Myeloproliferative Neoplasms: Types, Symptoms, and Treatment

Myeloproliferative neoplasms (MPNs) are rare blood cancers that occur when the bone marrow produces too many blood cells, including red blood cells, white blood cells, or platelets1 . These disorders often develop slowly and may remain stable for years, but they can also lead to serious complications such as blood clots or progression to acute leukemia2 . With advances in diagnosis and treatment, many patients live for several years with careful management3 .

“The term myeloproliferative neoplasms basically means that the body is producing too many cells, either red blood cells, platelets, or white blood cells.”13

Types of Myeloproliferative Neoplasms

Myeloproliferative neoplasms are clonal disorders of hematopoietic stem cells in the bone marrow that cause abnormal proliferation of one or more blood cell lineages4 . These stem cells normally give rise to all blood cells, including red blood cells, white blood cells, and platelets5 . MPNs are classified based on the predominant myeloid cell type that proliferates excessively6 .

The main types of MPNs include:

Polycythemia Vera (PV): Characterized by overproduction of red blood cells, often accompanied by elevated white blood cells and platelets. This leads to thickened blood and increased risk of clotting4 1.
Essential Thrombocythemia (ET): Marked by elevated platelet counts due to clonal proliferation of megakaryocytes, increasing the risk of thrombosis and bleeding4 1.
Primary Myelofibrosis (PMF): Features bone marrow fibrosis (scarring) that disrupts normal blood cell production, often causing anemia, low platelet counts, and splenomegaly7 1.
Chronic Myeloid Leukemia (CML): Defined by the presence of the Philadelphia chromosome (BCR-ABL1 fusion gene), leading to excessive proliferation of myeloid precursors, especially immature white blood cells8 .
Chronic Neutrophilic Leukemia (CNL): A rare MPN with sustained neutrophilia and granulocytic hyperplasia in the bone marrow9 .
Chronic Eosinophilic Leukemia (CEL): Characterized by clonal eosinophil proliferation affecting multiple organs9 .

MPNs are further classified as either Philadelphia chromosome-positive (e.g., CML) or Philadelphia chromosome-negative (classical MPNs such as PV, ET, and PMF) 410.

“Significant progress has been made in the last 20 years, allowing an ‘operational’ or ‘functional’ cure of most patients with chronic myeloid leukemia (CML), a type of myeloproliferative neoplasm previously associated with a median life expectancy of about five years.”
— Nikolai Podoltsev, MD, PhD, Yale Medicine10

Myeloproliferative Neoplasm Symptoms

Symptoms of MPNs vary depending on the subtype and disease progression. Many patients are asymptomatic at diagnosis due to the slow progression of the disease3 . When symptoms occur, they often relate to abnormal blood counts, marrow failure, or organ enlargement.

Common symptoms include:

Fatigue, weakness, and anemia-related symptoms such as shortness of breath11 1.
Headaches, dizziness, and visual disturbances, especially in PV due to hyperviscosity4 1.
Easy bruising, bleeding from gums or nose, and bleeding in the gastrointestinal or urinary tract, often related to platelet dysfunction or thrombocytopenia3 1.
Night sweats, fever, and weight loss, which may indicate disease progression or systemic inflammation7 1.
Splenomegaly causing abdominal fullness, discomfort, or early satiety7 1.
Itchy skin (pruritus), particularly after hot showers, common in PV1 .
Bone pain and bone tenderness, especially in PMF and CML8 1.

Specific MPN symptoms by subtype:

Chronic Eosinophilic Leukemia: Rash, fatigue, fever, and organ-specific symptoms due to eosinophil infiltration9 1.
Chronic Myeloid Leukemia and Chronic Neutrophilic Leukemia: Bone pain, night sweats, fever, fatigue, bruising, and weight loss8 1.
Essential Thrombocythemia: Bruising, bleeding, and thrombotic events such as stroke or heart attack4 1.
Polycythemia Vera: Headaches, dizziness, fatigue, blurred vision, and itching4 1.
Primary Myelofibrosis: Fatigue, anemia, night sweats, fever, weight loss, itching, abdominal fullness, and bone pain7 1.

Many MPN symptoms overlap with other conditions, making diagnosis challenging. Routine blood tests often reveal abnormal counts before symptoms appear, highlighting the importance of regular health checkups1 3.

Causes and Risk Factors

MPNs arise from acquired genetic mutations in hematopoietic stem cells that cause uncontrolled proliferation4 . These mutations activate signaling pathways that promote cell growth and survival, disrupting normal blood cell production5 .

Key genetic mutations involved include:

JAK2 V617F mutation: Present in most PV cases and a significant proportion of ET and PMF patients, leading to constant activation of the JAK-STAT pathway and excessive blood cell production12 5.
MPL mutations: Affect the thrombopoietin receptor, causing increased platelet production, mainly in ET and PMF12 5.
CALR mutations: Common in JAK2-negative ET and PMF cases, also driving abnormal cell proliferation12 .

The Philadelphia chromosome (BCR-ABL1 fusion gene) is the hallmark of CML, resulting from a chromosomal translocation that produces a constitutively active tyrosine kinase promoting myeloid cell proliferation8 .

Risk factors for developing MPNs include:

Age over 50, with most diagnoses occurring around age 654 3.
Exposure to high doses of radiation or certain toxins such as benzene2 .
Family history and inherited predisposition in rare cases2 .
Clonal hematopoiesis of indeterminate potential (CHIP), a common age-related phenomenon involving mutant blood cells, may increase MPN risk13 .

Excessive proliferation of blood cells can suppress normal hematopoiesis, leading to cytopenias that cause fatigue, bleeding, and infections11 . Progressive disease may cause splenomegaly and related symptoms7 .

Diagnosing Myeloproliferative Neoplasms

Diagnosis of MPNs involves a combination of clinical evaluation, laboratory tests, and genetic studies3 . Because symptoms can be vague or absent, routine blood counts often provide the first clue3 .

Diagnostic steps include:

Complete Blood Count (CBC): Detects elevated or abnormal levels of red blood cells, white blood cells, or platelets3 .
Peripheral Blood Smear: Examines blood cell morphology for abnormalities characteristic of MPNs3 .
Bone Marrow Biopsy and Aspiration: Assesses marrow cellularity, fibrosis, and abnormal cell populations3 .
Molecular Testing: Detects driver mutations such as JAK2, CALR, MPL, and BCR-ABL1 to confirm diagnosis and subtype4 123.
Biochemical Panels: Evaluate organ function and detect complications3 .

The presence of the Philadelphia chromosome or BCR-ABL1 fusion gene confirms CML diagnosis8 . Low serum erythropoietin levels support PV diagnosis10 . Genetic testing is essential for differentiating MPNs from other causes of abnormal blood counts13 .

The exact etiology of myeloproliferative neoplasms (MPNs) remains unclear, though genetic mutations play a central role4 .

Myeloproliferative Neoplasm Treatments

Treatment of MPNs aims to control symptoms, reduce blood cell counts, prevent complications such as thrombosis, and improve quality of life3 . The approach varies by MPN subtype, disease risk, and patient factors3 .

The median age at diagnosis for myeloproliferative neoplasms (MPNs) is around 65 years3 .

Common treatment options include:

Phlebotomy: Regular removal of blood to reduce red cell mass in PV1 10.
Cytoreductive Therapy: Medications like hydroxyurea reduce blood cell production in PV, ET, and PMF3 1.
JAK Inhibitors: Drugs such as ruxolitinib improve symptoms, reduce spleen size, and control blood counts, especially in myelofibrosis14 15.
Interferon-alpha: Used in PV and ET to reduce blood counts and potentially modify disease by targeting mutant cells16 13.
Low-dose Aspirin: Reduces the risk of blood clots in PV and ET10 .
Stem Cell Transplant: The only curative option, reserved for eligible patients with advanced or high-risk disease1 17.
Supportive Care: Blood transfusions, symptom management, and monitoring for disease progression3 .

Treatment goals focus on preventing thrombosis, managing symptoms, and maintaining quality of life rather than curing the disease in most cases3 .

MPN treatment includes cytoreductive therapy, JAK inhibitors, stem cell transplant, symptom management, and supportive care15 .

MPN Prevention Strategies

Currently, there are no established preventive measures for MPNs due to their genetic origin and acquired mutations in hematopoietic stem cells4 5. The mutations that cause MPNs cannot be reversed or prevented with existing therapies5 .

Management focuses on:

Early diagnosis and treatment to reduce complications3 .
Individualized therapy to slow disease progression and improve symptoms3 .
Ongoing monitoring to adjust treatment in response to disease changes or resistance15 .
Avoiding known risk factors such as exposure to radiation and toxins when possible2 .

Close follow-up with specialists is critical to optimize treatment outcomes and manage disease progression3 .

The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptom responses, improved quality of life, and overall survival14 .

MPNs are part of a broader group of blood cancers originating from malignant hematopoietic cells5 . They differ from leukemias, which involve immature blast cells, whereas MPNs involve proliferation of mature blood cells5 .

Related conditions include:

Acute Myeloid Leukemia (AML): A fast-growing cancer with proliferation of immature myeloid blasts, which can arise as a progression from MPNs18 .
Myelodysplastic Syndromes (MDS): Disorders characterized by ineffective blood cell production and abnormal marrow cells17 .
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN): Hybrid disorders with features of both MDS and MPN19 20.

MPNs may progress to AML, especially in advanced stages or with high-risk mutations18 .

Living With Myeloproliferative Neoplasms

Living with an MPN involves managing chronic symptoms, monitoring for disease progression, and maintaining quality of life21 3. Symptom burden can be significant, affecting physical and mental health22 .

Key aspects of living with MPNs:

Regular follow-up with healthcare providers for monitoring and treatment adjustments3 .
Multidisciplinary care to address symptoms, complications, and psychosocial needs21 .
Awareness of signs of disease progression or complications, such as new bruising, bleeding, or worsening fatigue3 .
Support for psychological distress, including counseling and support groups22 .
Lifestyle modifications such as healthy diet, exercise, and stress management to support overall health3 2.

MPNs may evolve into fibrotic stages or transform into acute leukemia, requiring close monitoring18 .

Many patients with MPNs report psychological distress and impaired quality of life, highlighting the importance of comprehensive care that includes mental health support22 .

Myeloproliferative Neoplasm FAQs

Are MPNs considered cancers?
Yes, the World Health Organization classifies MPNs as blood cancers because they involve uncontrolled production of blood cells due to genetic mutations2 .

Can MPNs be cured?
Stem cell transplantation is the only potentially curative treatment, but it is suitable for only a minority of patients due to its risks1 17. Most treatments focus on symptom control and preventing complications.

What is the prognosis for MPN patients?
Survival varies by subtype and treatment. For example, CML patients have a 90% five-year survival rate with targeted therapies, while PV and ET patients often live many years with proper management3 10.

How are MPNs diagnosed?
Diagnosis involves blood tests, bone marrow biopsy, and genetic testing for mutations such as JAK2, CALR, MPL, and BCR-ABL13 4.

What lifestyle changes can help manage MPNs?
Maintaining a healthy diet, exercising, managing stress, and avoiding smoking can support overall health and symptom management3 2.